Changes in Ki-67 in Residual Tumor and Outcome of Primary Inflammatory Breast Cancer Treated With Trimodality Therapy
-
Published:2022-07
Issue:5
Volume:22
Page:e655-e663
-
ISSN:1526-8209
-
Container-title:Clinical Breast Cancer
-
language:en
-
Short-container-title:Clinical Breast Cancer
Author:
Song ZhengORCID,
Li Chunyan,
Zhou Dongdong,
Liu Jingjing,
Qian Xiaolong,
Zhang Jin
Subject
Cancer Research,Oncology
Reference34 articles.
1. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment;Dawood;Ann Oncol,2011
2. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center;Ueno;Cancer Chemother Pharmacol,1997
3. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: a population-based study from the SEER program;Li;Oncotarget,2017
4. Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge;Vermeulen;Cancer,2010
5. Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome;Matro;Clin Breast Cancer,2015
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献